<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04844892</url>
  </required_header>
  <id_info>
    <org_study_id>P-400</org_study_id>
    <nct_id>NCT04844892</nct_id>
  </id_info>
  <brief_title>Phrenic Nerve Stimulation-Induced Lung ReAeration Trial</brief_title>
  <acronym>PIRAT</acronym>
  <official_title>A Protocol Investigating the Impact of Lungpacer PROTECT Diaphragm Pacing Therapy on Gas Exchange, Hemodynamics, Regional Lung Ventilation and Atelectasis in Patients Presenting With Moderate ARDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lungpacer Medical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lungpacer Medical Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Lungpacer PROTECT Diaphragm Pacing Therapy System (DPTS) is a temporary,&#xD;
      percutaneously-placed, transvenous, phrenic nerve-stimulating device intended to stimulate&#xD;
      the diaphragm to preserve and improve inspiratory muscle strength in mechanically ventilated&#xD;
      patients. The purpose of the PROTECT DPTS is to improve gas exchange, regional lung&#xD;
      ventilation, and hemodynamics, and decrease atelectasis in patients presenting with acute&#xD;
      respiratory distress syndrome (ARDS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PIRAT clinical study is intended to assess the feasibility, safety and effectiveness of&#xD;
      transvenous phrenic-nerve-stimulating diaphragm pacing on clinical outcomes in mechanically&#xD;
      ventilated patients. By delivering electrical stimulation to the phrenic nerves, which in&#xD;
      turn causes the diaphragm muscle to contract, the PROTECT DPTS is intended to protect the&#xD;
      diaphragm from atrophy and preserve lung mechanics to reduce lung inflammation and injury&#xD;
      associated with short-term mechanical ventilation. Sustained lung and diaphragm health during&#xD;
      early mechanical ventilation is expected to reduce the risk of comorbidities, improve&#xD;
      clinical outcomes such as weaning success, and thereby reduce the number of patients who&#xD;
      require prolonged mechanical ventilation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in PaO2/FiO2 ratio</measure>
    <time_frame>Day 1</time_frame>
    <description>The changes in PaO2/FiO2 ratio during each acute standard of care ventilation and acute PROTECT pacing therapy session.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful LIVE catheter placement</measure>
    <time_frame>Day 1</time_frame>
    <description>LIVE Catheter was successfully inserted into the left subclavian vein, positioned in accordance with the LIVE Catheter IFU, and the diaphragm was stimulated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alveolar-arterial (A-a) gradient</measure>
    <time_frame>Day 1</time_frame>
    <description>Alveolar-arterial (A-a) gradient documenting gas exchange during each acute standard of care ventilation and acute PROTECT pacing therapy session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output index</measure>
    <time_frame>Day 1</time_frame>
    <description>Pulse contour cardiac output index assessed by transpulmonary thermodilution during each acute standard of care ventilation and acute PROTECT pacing therapy session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional lung ventilation</measure>
    <time_frame>Day 1</time_frame>
    <description>Regional lung ventilation assessed using electrical impedance tomography during each acute standard of care ventilation and acute PROTECT pacing therapy session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional lung atelectasis</measure>
    <time_frame>Day 1</time_frame>
    <description>Regional lung atelectasis assessed using electrical impedance tomography during each acute standard of care ventilation and acute PROTECT pacing therapy session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>Day 5</time_frame>
    <description>Occurrence of pneumothorax, significant bleeding and desaturation serious adverse events.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Days until successful weaning</measure>
    <time_frame>Day 5</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 5</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>Ventilation Therapy; Complications</condition>
  <arm_group>
    <arm_group_label>PROTECT Diaphragm Pacing Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lungpacer PROTECT Diaphragm Pacing Therapy</intervention_name>
    <description>PROTECT diaphragm pacing therapy is intended to stimulate the diaphragm to preserve and improve inspiratory muscle strength in mechanically ventilated patients.</description>
    <arm_group_label>PROTECT Diaphragm Pacing Therapy</arm_group_label>
    <other_name>Lungpacer PROTECT DPTS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are 18 years or older&#xD;
&#xD;
          -  Have been mechanically ventilated due to moderate ARDS for 48-120h&#xD;
&#xD;
          -  Have a PaO2/FiO2 ratio &lt; 200 and &gt; 100 at the time of screening with PEEP ≥ 5 cmH2O&#xD;
&#xD;
          -  Are expected to remain on mechanical ventilation ≥ 48 hours&#xD;
&#xD;
          -  Are under continuous sedation with Richmond Agitation Sedation Scale (RASS) ≤ -3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Septic shock with hemodynamic instability (norepinephrine or epinephrine &lt; 0.5&#xD;
             gamma/kg/min)&#xD;
&#xD;
          -  Catheter access to left subclavian vein deemed impossible&#xD;
&#xD;
          -  Use of neuromuscular blocking agents within last 12 hours&#xD;
&#xD;
          -  Bacteremia within the last 48 hours or uncontrolled source of infection&#xD;
&#xD;
          -  Currently on ECMO&#xD;
&#xD;
          -  Enrolled in any other study of an investigational drug or device, which may affect the&#xD;
             outcomes of the current study&#xD;
&#xD;
          -  Pre-existing neurological, neuromuscular or muscular disorder that could affect the&#xD;
             respiratory muscles&#xD;
&#xD;
          -  BMI &gt;45 kg/m2&#xD;
&#xD;
          -  Known or suspected phrenic nerve paralysis&#xD;
&#xD;
          -  Any electrical device (implanted or external) that may be prone to interaction with or&#xD;
             interference from the Lungpacer PROTECT DPTS, including neurological pacing/stimulator&#xD;
             devices and cardiac pacemakers and defibrillators&#xD;
&#xD;
          -  No affiliation to the French health insurance system&#xD;
&#xD;
          -  Under curatorship&#xD;
&#xD;
          -  Imprisoned&#xD;
&#xD;
          -  Known or suspected to be pregnant or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Dres, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP Hôpital La Pitié-Salpêtrière</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nawzer Mehta, PhD</last_name>
    <phone>4844809667</phone>
    <email>nmehta@lungpacer.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Benoit Hallier</last_name>
    <email>bhallier@lungpacer.com</email>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

